Ilex paraguariensis提取物对骨质细胞表现型表达的影响
Antônio Secco Martorano1,2, Walter Raucci Neto3, Lucas Novaes Teixeira4
1School of Dentistry of Ribeirão Preto, University of São Paulo, São Paulo, SP, Brazil. antoniomartora@gmail.com.
Molecular biology reports
|June 2, 2025
概括
伊力克斯帕拉瓜里内斯提取物 (Ilox® Micro) 通过增强骨质细胞分化,显示出骨再生的潜力. 这项研究发现,它在体外对骨质母细胞表型发育的关键因素产生积极影响.
科学领域:
- 生物材料科学 生物材料科学
- 细胞生物学 细胞生物学
- 自然产品 化学 化学
背景情况:
- 饮食补充剂和天然化合物被探索用于骨再生.
- Ilex paraguariensis (yerba mate) 的益处在其他组织中已知,但在骨中未得到充分研究.
- 这项研究调查了Ilex paraguariensis提取物对骨质母细胞分化的影响.
研究的目的:
- 评估Ilox®微微提取物对体外骨质母细胞分化的影响.
- 评估提取物的抗氧化能力和含量.
- 确定提取物对骨质细胞活力,基因表达和矩阵矿物化的影响.
主要方法:
- 用不同度的Ilox® Micro提取物治疗的骨质母细胞 (UMR-106).
- 通过实时PCR进行抗氧化能力,总含量,细胞活力 (活/死,复苏林) 和基因表达 (Runx-2, Sp7, Col1a1, Alpl, Ibsp, Bglap) 的测试.
- 对于性酸酶 (ALP) 活性和矿化矩阵形成的现场染色.
主要成果:
- 伊洛克斯®微微提取物证明了剂量依赖的细胞活力和增殖.
- 在60μg/mL时观察到Runx2和Bglap基因的升调.
- 在30μg/mL时增加ALP活性,在10和30μg/mL时趋向于增强矿化.
结论:
- 伊洛克斯®微微提取物在体外积极调节骨质细胞表型获得的关键方面.
- 提取物显示出作为增强骨再生策略的潜在代理商的承诺.
- 需要进一步的研究来探索其在骨组织工程中的治疗潜力.
相关概念视频
Osteoclasts in Bone Remodeling
3.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.9K
EPS and iPS Cells in Disease Research
3.2K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.2K


